Limits...
Hurdles and delays in access to anti-cancer drugs in Europe.

Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart M, Parent F - Ecancermedicalscience (2014)

Bottom Line: Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas.To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process.This review aims to describe the process and discuss the hurdles arising at each step.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels 1000, Belgium.

ABSTRACT
Demographic changes in the world population will cause a significant increase in the number of new cases of cancer. To handle this challenge, societies will need to adapt how they approach cancer prevention and treatment, with changes to the development and uptake of innovative anticancer drugs playing an important role. However, there are obstacles to implementing innovative drugs in clinical practice. Prior to being incorporated into daily practice, the drug must obtain regulatory and reimbursement approval, succeed in changing the prescription habits of physicians, and ultimately gain the compliance of individual patients. Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas. To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process. This review aims to describe the process and discuss the hurdles arising at each step.

No MeSH data available.


Related in: MedlinePlus

Drug hurdles: from drug target identification to patient compliance—the long way from the bench to the patient. EMA: European Medicines Agency; HTA: health technology assessment; P&R: pricing and reimbursement.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263523&req=5

figure1: Drug hurdles: from drug target identification to patient compliance—the long way from the bench to the patient. EMA: European Medicines Agency; HTA: health technology assessment; P&R: pricing and reimbursement.

Mentions: Medical innovation has a major impact on patient survival and longevity. Econometric approaches estimate that 40% of the improvement in life expectancy in recent years was related to the launch of innovative drugs [2]. Developing a drug and bringing it into clinical practice is a complex process involving multiple partners in several areas, including researchers, pharmaceutical companies, national governments, health authorities, the medical community, and patients. Several hurdles can arise during each stage of this process, i.e., during the drug development, the granting of access to the drug by regulators, and the adoption of the drug in clinical practice. An overview of the regulatory process to final administration to patients is fundamental to optimizing patient treatment and increasing the likelihood of implementing health innovation (Figure 1).


Hurdles and delays in access to anti-cancer drugs in Europe.

Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart M, Parent F - Ecancermedicalscience (2014)

Drug hurdles: from drug target identification to patient compliance—the long way from the bench to the patient. EMA: European Medicines Agency; HTA: health technology assessment; P&R: pricing and reimbursement.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263523&req=5

figure1: Drug hurdles: from drug target identification to patient compliance—the long way from the bench to the patient. EMA: European Medicines Agency; HTA: health technology assessment; P&R: pricing and reimbursement.
Mentions: Medical innovation has a major impact on patient survival and longevity. Econometric approaches estimate that 40% of the improvement in life expectancy in recent years was related to the launch of innovative drugs [2]. Developing a drug and bringing it into clinical practice is a complex process involving multiple partners in several areas, including researchers, pharmaceutical companies, national governments, health authorities, the medical community, and patients. Several hurdles can arise during each stage of this process, i.e., during the drug development, the granting of access to the drug by regulators, and the adoption of the drug in clinical practice. An overview of the regulatory process to final administration to patients is fundamental to optimizing patient treatment and increasing the likelihood of implementing health innovation (Figure 1).

Bottom Line: Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas.To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process.This review aims to describe the process and discuss the hurdles arising at each step.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels 1000, Belgium.

ABSTRACT
Demographic changes in the world population will cause a significant increase in the number of new cases of cancer. To handle this challenge, societies will need to adapt how they approach cancer prevention and treatment, with changes to the development and uptake of innovative anticancer drugs playing an important role. However, there are obstacles to implementing innovative drugs in clinical practice. Prior to being incorporated into daily practice, the drug must obtain regulatory and reimbursement approval, succeed in changing the prescription habits of physicians, and ultimately gain the compliance of individual patients. Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas. To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process. This review aims to describe the process and discuss the hurdles arising at each step.

No MeSH data available.


Related in: MedlinePlus